Legalized marijuana has a lot of investors having visions of lots of green. With legalization sweeping across the states, it seems to be a great time to invest in marijuana stocks. Unfortunately, it’s not.
Tag Archives: Value
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
If just a single clinical trial works in favor of Cara Therapeutics, it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
Over the trailing-12-month period through July 15, the average marijuana stock with a market cap in excess of $200 million — a dozen stocks in total, which excluded MedReleaf because it just went public a month ago — was up by 332%.
In this Cal Can Biz Expo interview, watch Kristen Fox, Editor-in-Chief of MJINews.com and Marijuana Industry News magazine, interview Sturges Karban, CEO of MJIC.
Warren Buffett is well known as the most successful investor of all time. Buffett spent his formative years under the tutelage of Benjamin Graham, who is known today as the “father of value investing.” Let’s see whether or not Aphria Inc. can pass Buffett’s mentor’s criteriea test.
Oh, how the mighty have fallen. Shares of Canopy Growth Corp. have dropped by over $6 a share, or 47.5%, since the middle of February.
If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?
There are many reasons why Canopyis falling faster than its peers, but a big reason is the fact that Canopy was one of the first firms to the party. Canopy was one of the only ways to invest in the emerging marijuana industry, but now it is just one of many options to get in on the marijuana party.
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
Last week, two marijuana stocks skyrocketed by a double-digit percentage. Let’s take a closer look at the possible “why” behind these moves.
Today we’re going to share seven essential tips that will help you save both time and money and invest in cannabis stocks as profitably as possible.
The recently debuted marijuana stock ETF, the Horizons Medical Marijuana Life Sciences ETF, has lost value for those who’ve decided to take the plunge.
A major Canadian medical marijuana player, Canopy Growth is a producer and retailer of medical cannabis products and oils in our neighbor to the north. It’s also the only other marijuana stock other than GW Pharmaceuticals to bear a $1 billion valuation.
Canopy Growth Corp.’s now down approximately 36% since my warning that the stock could be heading for a correction that would be triggered by the banned pesticides scandal.
Marijuana stocks are extremely risky. But, if things go right for these pot stocks over the next two to three years, they could be a steal for investors.
Watch Bradley Orr, CEO of Stratos, and Michael Katz, CEO of Evoxe, talk about processing and manufacturing cannabis at the World of Cannabis in Las Vegas.
Can marijuana stocks keep going higher? The answer could depend more on the laws of supply and demand than current U.S. laws.
With two marijuana stocks already sporting market caps over $1 billion, one of these four pot stocks is likely to be next.
There is an opportunity for excess profits in the Canadian marijuana industry as the market is now in a position to expand at a very high rate, as Canadians have received confirmation that the potential legalization will become a reality.
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
Aphria Inc. has been soaring since its graduation to the TSX last month. The company now has a $1.1 billion market cap and could pass Canopy Growth Corp. with its $1.74 billion market cap over the next few months. There’s no question Canopy stock has slowed down when compared to its peers like Aphria and Aurora Cannabis Inc
Marijuana stocks are riding high as the stock index is up for the eighth consecutive week.
Canopy Growth Corp. (TSX:CGC) has been on a wild ride in recent months, and investors who think the name has long-term potential are trying to decided when they should buy.
Canopy, previously listed on the Canadian Venture Exchange under stock symbol TWD (Tweed was the original company, later consolidated into Canopy), began trading publicly on the Toronto Stock Exchange in July amid great anticipation from investors and financial markets.
You had to have strong conviction to stay in this sector as an individual investor, but you also had to have a sense of humor. Sometimes it seemed like open mic night at the comedy club … you know, not always very funny.
For new long-term cannabis investors, especially in the learning stages, daily stock charts can be like the sirens of information.
The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.
Every good business idea starts with an unmet need. Josh Gordon, CEO and founder of The Bureau, sees an unmet need for cannabis consumers to transport, store and present their product with class.